132 related articles for article (PubMed ID: 26159352)
1. A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments.
Nanaware-Kharade N; Thakkar S; Gonzalez GA; Peterson EC
Sci Rep; 2015 Jul; 5():12060. PubMed ID: 26159352
[TBL] [Abstract][Full Text] [Related]
2. PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.
Reichard EE; Nanaware-Kharade N; Gonzalez GA; Thakkar S; Owens SM; Peterson EC
Pharm Res; 2016 Dec; 33(12):2954-2966. PubMed ID: 27620175
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: synthesis and in vitro characterization.
Nanaware-Kharade N; Gonzalez GA; Lay JO; Hendrickson HP; Peterson EC
Bioconjug Chem; 2012 Sep; 23(9):1864-72. PubMed ID: 22873701
[TBL] [Abstract][Full Text] [Related]
4. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.
Peterson EC; Laurenzana EM; Atchley WT; Hendrickson HP; Owens SM
J Pharmacol Exp Ther; 2008 Apr; 325(1):124-33. PubMed ID: 18192498
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
Gentry WB; Laurenzana EM; Williams DK; West JR; Berg RJ; Terlea T; Owens SM
Int Immunopharmacol; 2006 Jun; 6(6):968-77. PubMed ID: 16644483
[TBL] [Abstract][Full Text] [Related]
6. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.
Laurenzana EM; Byrnes-Blake KA; Milesi-Hallé A; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2003 Nov; 31(11):1320-6. PubMed ID: 14570763
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
[TBL] [Abstract][Full Text] [Related]
8. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats.
Milesi-Hallé A; Hendrickson HP; Laurenzana EM; Gentry WB; Owens SM
Toxicol Appl Pharmacol; 2005 Dec; 209(3):203-13. PubMed ID: 15916788
[TBL] [Abstract][Full Text] [Related]
9. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.
White SJ; Hendrickson HP; Atchley WT; Laurenzana EM; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2014 Aug; 42(8):1285-91. PubMed ID: 24839971
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of immunoassays with particles as labels: effect of antibody coupling using dendrimers as linkers.
Gubala V; Lynam CC; Nooney R; Hearty S; McDonnell B; Heydon K; O'Kennedy R; MacCraith BD; Williams DE
Analyst; 2011 Jun; 136(12):2533-41. PubMed ID: 21541412
[TBL] [Abstract][Full Text] [Related]
12. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.
Hambuchen MD; Rüedi-Bettschen D; Williams DK; Hendrickson H; Owens SM
Vaccine; 2014 Oct; 32(47):6213-9. PubMed ID: 25252196
[TBL] [Abstract][Full Text] [Related]
13. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration.
Rivière GJ; Gentry WB; Owens SM
J Pharmacol Exp Ther; 2000 Mar; 292(3):1042-7. PubMed ID: 10688621
[TBL] [Abstract][Full Text] [Related]
14. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection.
Hendrickson H; Laurenzana E; Owens SM
AAPS J; 2006 Nov; 8(4):E709-17. PubMed ID: 17233534
[TBL] [Abstract][Full Text] [Related]
15. Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering.
Thakkar S; Nanaware-Kharade N; Celikel R; Peterson EC; Varughese KI
Sci Rep; 2014 Jan; 4():3673. PubMed ID: 24419156
[TBL] [Abstract][Full Text] [Related]
16. Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.
Hay CE; Gonzalez GA; Ewing LE; Reichard EE; Hambuchen MD; Nanaware-Kharade N; Alam S; Bolden CT; Owens SM; Margaritis P; Peterson EC
PLoS One; 2018; 13(6):e0200060. PubMed ID: 29958300
[TBL] [Abstract][Full Text] [Related]
17. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats.
Byrnes-Blake KA; Carroll FI; Abraham P; Owens SM
Int Immunopharmacol; 2001 Feb; 1(2):329-38. PubMed ID: 11360933
[TBL] [Abstract][Full Text] [Related]
18. PEGylated dendrimer-entrapped gold nanoparticles for in vivo blood pool and tumor imaging by computed tomography.
Peng C; Zheng L; Chen Q; Shen M; Guo R; Wang H; Cao X; Zhang G; Shi X
Biomaterials; 2012 Feb; 33(4):1107-19. PubMed ID: 22061490
[TBL] [Abstract][Full Text] [Related]
19. (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration.
Gentry WB; Ghafoor AU; Wessinger WD; Laurenzana EM; Hendrickson HP; Owens SM
Pharmacol Biochem Behav; 2004 Dec; 79(4):751-60. PubMed ID: 15582684
[TBL] [Abstract][Full Text] [Related]
20. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]